UCB, BE0003739530

UCB wins FDA approval for ZILBRYSQ autoinjector and UCB stock costs EUR 203.00

Published on 10/18/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB gets FDA approval for a ZILBRYSQ autoinjector on October 16, 2026. UCB stock costs EUR 203.00 in weekend trading on October 18, 2026.

Regulatory update and trading date

  • UCB announced FDA approval for the ZILBRYSQ autoinjector on October 16, 2026.
  • UCB stock trades in weekend trading at Lang & Schwarz at EUR 203.00 at 5:45 p.m. CEST on October 18, 2026.
  • The next Xetra session is scheduled for October 19, 2026.
  • UCB expects commercial availability in the first quarter of 2027.
UCB S.A. mit ISIN BE0003739530 als Flatlay: Aktienzertifikat, ISIN-Karte, Molekülmodell und Laborutensilien arrangiert, Illustration mit AI erstellt.

UCB announced on October 16, 2026, that the U.S. Food and Drug Administration approved a self-administered once-daily autoinjector option for ZILBRYSQ in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive, according to UCB. At 5:45 p.m. CEST on October 18, 2026, UCB was priced at EUR 203.00 in weekend trading at Lang & Schwarz.

Market context: Market report Euro Stoxx 50.

Weekend trading

The Lang & Schwarz price was recorded during the stated weekend-trading phase. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of UCB stock.

FDA approval

UCB said the approval adds a second self-administration option to the existing prefilled syringe. The company reported complete dose delivery in 99.8 percent of 449 autoinjector administrations and said it expects commercial availability in the first quarter of 2027, according to UCB.

Next Xetra session

The next Xetra session is scheduled for October 19, 2026. The company announcement and the weekend-trading price are separate dated items.

Disclaimer...
en | BE0003739530 | UCB | boerse | 70355051 | bgmi